Zhijiang Biotech announced that the “Molecular Diagnosis Engineering R&D Center Construction Project” and “Marketing and Service Network Upgrade Project” have reached the expected state of use and are scheduled to be completed on July 28, saving 206 million yuan in capital. Of these, 61.496 million yuan is to be invested in the “Product Research and Development Project”, and 145 million yuan is to be used for the new “Diagnosis and Treatment Technology Research and Development Project”. In addition, the company plans to use 60 million yuan of capital raised to increase capital to two wholly-owned subsidiary companies to implement the project. The matter has been reviewed by the board of directors and is still subject to approval by the shareholders' meeting.

Zhijiang Biotech announced that the “Molecular Diagnosis Engineering R&D Center Construction Project” and “Marketing and Service Network Upgrade Project” have reached the expected state of use and are scheduled to be completed on July 28, saving 206 million yuan in capital. Of these, 61.496 million yuan is to be invested in the “Product Research and Development Project”, and 145 million yuan is to be used for the new “Diagnosis and Treatment Technology Research and Development Project”. In addition, the company plans to use 60 million yuan of capital raised to increase capital to two wholly-owned subsidiary companies to implement the project. The matter has been reviewed by the board of directors and is still subject to approval by the shareholders' meeting.